Extract
Respiratory infections, including tuberculosis, represent one of the leading causes of morbidity and mortality across the world. They represent the deadliest communicable diseases causing 3.0 million deaths worldwide in 2016 [1]. The burden of respiratory infections can be unbearable for some health systems: they represent one of the most common reasons for doctor visits, regardless of age and sex [2].
Abstract
ERS has developed a syllabus for postgraduate training in respiratory infections to guide programme designers http://ow.ly/xJ0R30m8CYB
Acknowledgements
The task force would like to acknowledge Albert Osterhaus (Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany) for his work on this project.
The authors affiliations are as follows. Stefano Aliberti: Dept of Pathophysiology and Transplantation, University of Milano, Milan, Italy, and Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. Amy Farr and Nathalie Tabin: European Respiratory Society, Educational Activities Dept, Lausanne, Switzerland. Francesco Blasi: Dept of Pathophysiology and Transplantation, University of Milano, Milan, Italy. Antoni Torres: Pneumology Dept, Hospital CLINIC, University of Barcelona, IDIBAPS, CIBERE, Barcelona, Spain. Mark Woodhead: Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Giovanni Battista Migliori: Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy. Giovanni Sotgiu: Clinical Epidemiology and Medical Statistics Unit, Dept of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. George Dimopoulos: Dept of Critical Care, University Hospital ATTIKON, Medical School, National and Kapodistrian University of Athens, Athens, Greece. James D. Chalmers: Dept of Respiratory Medicine, Ninewells Hospital and Medical School, Dundee, UK. Felix C. Ringshausen: Dept of Respiratory Medicine, Hannover Medical School and German Center for Lung Research (DZL), Hannover, Germany. Michael R. Loebinger: Host Defence Unit, Royal Brompton Hospital, London, UK and National Heart and Lung Institute, Imperial College, London, UK. Robert Read: Academic Unit of Infection and Immunity, University of Sheffield Medical School, Sheffield, UK. Gernot Rohde: Medical clinic I, Dept of Respiratory Medicine, Goethe University Hospital, Frankfurt/Main, Germany.
Footnotes
Conflict of interest: S. Aliberti has nothing to disclose.
Conflict of interest: A. Farr is an employee of the European Respiratory Society.
Conflict of interest: N. Tabin is an employee of the European Respiratory Society.
Conflict of interest: F. Blasi has nothing to disclose.
Conflict of interest: A. Torres has nothing to disclose.
Conflict of interest: M. Woodhead reports an honorarium for a lecture at European Pneumoupdate in 2016, 2017 and 2018.
Conflict of interest: G.B. Migliori has nothing to disclose.
Conflict of interest: G. Sotgiu has nothing to disclose.
Conflict of interest: G. Dimopoulos has nothing to disclose.
Conflict of interest: J.D. Chalmers reports grants and personal fees from Glaxosmithkline, Grifols, Boehringer-Ingelheim and Insmed, grants from Astrazeneca and Bayer Healthcare, personal fees from Aradigm, Pfizer and Napp, all outside the submitted work.
Conflict of interest: F.C. Ringshausen reports grants, personal fees and other from Bayer HealthCare (research support, consulting, lecture fees and support of patient educational events), grants and personal fees from Grifols Germany (research support and consulting), grants and personal fees from Insmed Germany (research support, consulting and reimbursement for study participation/patient recruitment), personal fees from Brahms/Thermo Fisher Scientific (consulting), personal fees from Astra Zeneca (lecture fees), personal fees and other from Forest (consulting and support of patient educational events), personal fees from Cellestis/Qiagen (lecture fees), personal fees and other from Chiesi (travel reimbursement and support of patient educational events), other from Abbott (support of patient educational events), personal fees and other from Gilead (travel reimbursement and support of patient educational events), other from Pfizer (support of patient educational events), other from Oxycare (support of patient educational events), other from Novartis (support of patient educational events), other from Heinen & Löwenstein (support of patient educational events), other from MSD (support of patient educational events), grants and other from InfectoPharm (research support and support of patient educational events), all outside the submitted work.
Conflict of interest: M.R. Loebinger has nothing to disclose.
Conflict of interest: R. Read has nothing to disclose.
Conflict of interest: G. Rohde reports personal fees from Pfizer, Boehringer Ingelheim, Solvay, GSK, Essex Pharma, MSD, Roche and Novartis for lectures including service on speakers’ bureaus outside the submitted work and/or consultancy during advisory board meeting and personal fees from GSK for travel accommodations/meeting expenses, outside the submitted work.
- Copyright ©ERS 2018
Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.